BMC Cancer Oncology

Elevated classical soluble HLA class I molecules in breast cancer patients are associated with favorable disease outcome

Christian M. Tegeler, Jonas Rieth, André Koch, Anna Seller, Dominik Dannehl, Markus Hahn, Tobias Engler, Andreas D. Hartkopf, Sara Y. Brucker, Juliane S. Walz, Jonas S. Heitmann, Annika Nelde
Springer Nature · 2026-11-20 · DOI 10.1186/s12885-026-17386-0

Abstract

Abstract Background T cell recognition of human leukocyte antigen (HLA)-presented peptides plays a central role in immunosurveillance of malignant disease. Besides HLA molecules on cell surfaces, soluble HLA molecules (sHLA) are released in the blood and suggested to impact cellular immune responses. Methods Here, we investigate classical sHLA class I (HLA-A, -B, -C) molecules in pretreatment serum from 191 patients, either with invasive breast cancer (BC, n = 140) or with ductal carcinoma in situ (DCIS, n = 51), in relation to clinical parameters and survival with a follow-up time of up to 10 years. Results Classical sHLA class I serum levels were significantly elevated in patients with DCIS and invasive BC compared to a healthy control cohort. sHLA levels did not differ across molecular subtypes or menopausal status. Of note, higher sHLA class I levels at time of diagnosis were associated with prolonged overall survival independent of age and metastatic status. Conclusions The findings of this study reveal first insights on classical sHLA class I molecules in BC patients suggesting an association of higher sHLA class I levels with favorable overall survival that warrants mechanistic investigation and identify sHLA as a potential candidate biomarker for further validation.

Read at publisher →